Literature DB >> 32969904

68Ga-FAPI and 18F-FDG PET/CT Images in a Patient With Extrapulmonary Tuberculosis Mimicking Malignant Tumor.

Bingxin Gu1, Zhiguo Luo2, Xinhong He3, Jian Wang4, Shaoli Song1.   

Abstract

Extrapulmonary tuberculosis (TB) is difficult to diagnose. Here, we report a case of extrapulmonary TB in a 68-year-old woman presented with mental fatigue, poor appetite, and weight loss. F-FDG PET/CT revealed elevated F-FDG uptake in the left inferior cervical, left supraclavicular, mediastinal, and splenic hilum lymph nodes and spleen, which were suspected of malignant tumor. To further differentiate benign and malignant diseases, Ga-FAPI PET/CT was performed. Ga-FAPI PET/CT also showed intense Ga-FAPI uptake in the previously mentioned FDG-avid lesions. However, biopsy of the left supraclavicular lymph node demonstrated the presence of TB.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32969904      PMCID: PMC7531500          DOI: 10.1097/RLU.0000000000003279

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   10.782


A 68-year-old woman presented with mental fatigue, poor appetite, and weight loss for 1 month. In addition, physical examination revealed enlarged left supraclavicular lymph node. She had no fever, cough, expectoration, or nighttime sweating. Her leukocyte count was 18.1 × 109/L (reference, 3.5–9.5 × 109/L), neutrophil count was 14.5 × 109/L (reference, 1.8–6.3 × 109/L), platelet count was 672 × 109/L (reference, 125–350 × 109/L), and serum creatinine level was within the reference range. 18F-FDG PET/CT was performed to aid in diagnosis. As showed in MIP of 18F-FDG PET, elevated 18F-FDG uptake in left inferior cervical, left supraclavicular, mediastinal, and splenic hilum lymph nodes (A, arrows), and spleen (A, arrowhead) were revealed. Representative lymph node (B–D, arrows; SUVmax, 16.9) and spleen lesions (E–G, arrowhead; SUVmax, 12.0) in the axial CT, PET, and fusion PET/CT images were exhibited. However, it is not easy to make a diagnosis with 18F-FDG PET/CT only. 68Ga-FAPI PET/CT was performed to further differentiate benign and malignant diseases. The patient was enrolled in the prospective study evaluating the role of 68Ga-FAPI PET/CT in the management of malignant tumors, which was approved by Shanghai Cancer Center Institutional Review Board (ID 2004216-25), and written informed consent was obtained from the patient. The MIP, axial CT, PET, and fusion PET/CT images of 68Ga-FAPI PET/CT showed intense 68Ga-FAPI uptake in the aforementioned FDG-avid lymph nodes (A–D; arrows, SUVmax, 20.1) and spleen lesions (A, E–G, arrowhead; SUVmax, 11.7). According to the results of 18F-FDG and 68Ga-FAPI PET/CT, the most likely diagnosis was malignant tumor. However, biopsy of the left supraclavicular lymph node demonstrated the presence of tuberculosis (TB). Granulomatous nodules composed of epithelioid cells, caseous necrosis, and inflammatory cells or lymphocytes were observed in microscopic section of hematoxylin-eosin stain (A, original magnification ×10) and Liu’s stain (B, original magnification ×20). The 68Ga-FAPI is developed to detect the expression of fibroblast activation protein (FAP).[1-3] FAP is an overexpression in more than 90% of epithelial carcinomas and some mesenchymal tumors, and recent studies showed that 68Ga-FAPI might be a broad-spectrum tumor PET agent.[4-6] However, high uptake of 68Ga-FAPI was also found in nontumorous lesions, including wound healing, inflammation, fibrosis, and so on.[7,8] This case again highlighted that 68Ga-FAPI could gather in nontumorous lesions. Even so, the positive founding of 68Ga-FAPI in extrapulmonary TB lesions indicates that 68Ga-FAPI could serve as a probe in diagnosis and response evaluation of TB.
  8 in total

1.  Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein.

Authors:  Thomas Lindner; Anastasia Loktev; Annette Altmann; Frederik Giesel; Clemens Kratochwil; Jürgen Debus; Dirk Jäger; Walter Mier; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2018-04-06       Impact factor: 10.057

2.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.

Authors:  Clemens Kratochwil; Paul Flechsig; Thomas Lindner; Labidi Abderrahim; Annette Altmann; Walter Mier; Sebastian Adeberg; Hendrik Rathke; Manuel Röhrich; Hauke Winter; Peter K Plinkert; Frederik Marme; Matthias Lang; Hans-Ulrich Kauczor; Dirk Jäger; Jürgen Debus; Uwe Haberkorn; Frederik L Giesel
Journal:  J Nucl Med       Date:  2019-04-06       Impact factor: 10.057

3.  Recurrent Immunoglobulin G4-Related Disease Shown on 18F-FDG and 68Ga-FAPI PET/CT.

Authors:  Qingqing Pan; Yaping Luo; Wen Zhang
Journal:  Clin Nucl Med       Date:  2020-04       Impact factor: 7.794

4.  Intense FAPI Uptake in Inflammation May Mask the Tumor Activity of Pancreatic Cancer in 68Ga-FAPI PET/CT.

Authors:  Yaping Luo; Qingqing Pan; Wen Zhang; Fang Li
Journal:  Clin Nucl Med       Date:  2020-04       Impact factor: 7.794

5.  A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts.

Authors:  Anastasia Loktev; Thomas Lindner; Walter Mier; Jürgen Debus; Annette Altmann; Dirk Jäger; Frederik Giesel; Clemens Kratochwil; Philippe Barthe; Christian Roumestand; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2018-04-06       Impact factor: 10.057

6.  Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention.

Authors:  Anastasia Loktev; Thomas Lindner; Eva-Maria Burger; Annette Altmann; Frederik Giesel; Clemens Kratochwil; Jürgen Debus; Frederik Marmé; Dirk Jäger; Walter Mier; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2019-03-08       Impact factor: 10.057

7.  Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients.

Authors:  Catherine Meyer; Magnus Dahlbom; Thomas Lindner; Sebastien Vauclin; Christine Mona; Roger Slavik; Johannes Czernin; Uwe Haberkorn; Jeremie Calais
Journal:  J Nucl Med       Date:  2019-12-13       Impact factor: 10.057

8.  68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers.

Authors:  Frederik L Giesel; Clemens Kratochwil; Thomas Lindner; Manfred M Marschalek; Anastasia Loktev; Wencke Lehnert; Jürgen Debus; Dirk Jäger; Paul Flechsig; Annette Altmann; Walter Mier; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2018-08-02       Impact factor: 10.057

  8 in total
  8 in total

1.  Superiority of 68Ga-FAPI PET/CT scan in detecting additional lesions compared to 18FDG PET/CT scan in breast cancer.

Authors:  Umut Elboga; Ertan Sahin; Tulay Kus; Yusuf Burak Cayirli; Gokmen Aktas; Evren Uzun; Havva Yesil Cinkir; Fatih Teker; Ozlem Nuray Sever; Alper Aytekin; Latif Yilmaz; Aydin Aytekin; Ufuk Cimen; Vuslat Mumcu; Benan Kilbas; Y Zeki Çelen
Journal:  Ann Nucl Med       Date:  2021-08-26       Impact factor: 2.668

Review 2.  Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors:  Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-31       Impact factor: 10.057

Review 3.  FAPI-PET/CT in Cancer Imaging: A Potential Novel Molecule of the Century.

Authors:  Rong Huang; Yu Pu; Shun Huang; Conghui Yang; Fake Yang; Yongzhu Pu; Jindan Li; Long Chen; Yunchao Huang
Journal:  Front Oncol       Date:  2022-05-25       Impact factor: 5.738

4.  State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis.

Authors:  Martina Sollini; Margarita Kirienko; Fabrizia Gelardi; Francesco Fiz; Noemi Gozzi; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-25       Impact factor: 9.236

5.  Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?

Authors:  Hessamoddin Roustaei; Zahra Kiamanesh; Emran Askari; Ramin Sadeghi; Kamran Aryana; Giorgio Treglia
Journal:  Contrast Media Mol Imaging       Date:  2022-02-22       Impact factor: 3.161

6.  FAPI-04 Uptake in Healthy Tissues of Cancer Patients in 68Ga-FAPI-04 PET/CT Imaging.

Authors:  Cihan Gündoğan; Yunus Güzel; Canan Can; İhsan Kaplan; Halil Kömek
Journal:  Contrast Media Mol Imaging       Date:  2021-11-23       Impact factor: 3.161

7.  The Application of [68Ga]-Labeled FAPI-04 PET/CT for Targeting and Early Detection of Pancreatic Carcinoma in Patient-Derived Orthotopic Xenograft Models.

Authors:  He Zhang; Jiaze An; Pengpeng Wu; Caiqin Zhang; Yong Zhao; Dengxu Tan; Changhong Shi; Xu Ge
Journal:  Contrast Media Mol Imaging       Date:  2022-08-05       Impact factor: 3.009

Review 8.  Tuberculosis: Role of Nuclear Medicine and Molecular Imaging With Potential Impact of Neutrophil-Specific Tracers.

Authors:  Stuart More; Mohlopheni J Marakalala; Michael Sathekge
Journal:  Front Med (Lausanne)       Date:  2021-12-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.